FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer

The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population.

Anktiva (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin is now authorised for eligible patients with high-grade papillary-only disease, extending its previous indication for carcinoma in situ-associated bladder cancer.

The decision draws on evidence from the QUILT-3.032 development programme and regulatory consideration of related disease presentations, broadening treatment options for patients whose cancer has not responded to BCG.

Field	Content
Article Type	Approvals
Drug Name	Anktiva
Generic Name	Nogapendekin alfa inbakicept-pmln
Company	ImmunityBio
Regulatory Authority	U.S. Food and Drug Administration
Regulatory Decision	Expanded indication approval
New Indication	BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumours
Patient Population	Adults with high-grade papillary-only BCG-unresponsive NMIBC
Previously Approved Population	BCG-unresponsive NMIBC with carcinoma in situ
Treatment Regimen	Anktiva in combination with bacillus Calmette-Guérin (BCG)
Therapeutic Area	Oncology; bladder cancer
Therapeutic Modality	IL-15 receptor agonist immunotherapy
Clinical Evidence	QUILT-3.032 development programme and supporting regulatory evidence
Approval Significance	First FDA-approved treatment specifically for the high-grade papillary-only BCG-unresponsive NMIBC population
Geography	United States
What Happened	The FDA expanded Anktiva's indication to include high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer.
Why It Matters	The decision provides a newly authorised treatment option for a patient population with limited bladder-preserving therapeutic choices.
Supporting Context	The expanded indication builds on Anktiva's existing authorisation in BCG-unresponsive carcinoma in situ-associated disease.
Key Takeaway	Anktiva plus BCG is now FDA-approved for eligible adults with high-grade papillary-only BCG-unresponsive NMIBC.
What to Watch	Clinical guideline updates, physician adoption, reimbursement and longer-term treatment outcomes.
Primary Source	U.S. Food and Drug Administration
Relevant Date	14 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com